Drug Profile
Bitopertin - Disc Medicine
Alternative Names: DISC-1459; Heme synthesis modulator - Disc Medicine; R-1678; RG 6718; RG-6178; RG1678; RO-4917838Latest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Roche
- Developer Chugai Pharmaceutical; Disc Medicine; Roche
- Class Antianaemics; Antipsychotics; Behavioural disorder therapies; Piperazines; Pyridines; Skin disorder therapies; Small molecules
- Mechanism of Action Glycine transporter 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Erythropoietic protoporphyria
- Phase I/II Diamond-Blackfan syndrome
- Preclinical Myelodysplastic syndromes
- Discontinued Beta-thalassaemia; Obsessive-compulsive disorders; Schizophrenia
Most Recent Events
- 21 Mar 2024 Disc Medicine completed enrollment of phase II programme of bitopertin in erythropoietic porphyrias
- 13 Dec 2023 Updated safety and efficacy data from a phase II BEACON trial in Erythropoietic protoporphyria released by (Company)
- 09 Dec 2023 Pharmacodynamics data from a preclinical studies in Diamond-Blackfan syndrome presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)